The first decision is not a number. It is whether semaglutide is appropriate at all, which turns on indication, thyroid and endocrine history, pregnancy status, pancreatic and gallbladder history, kidney function, and what else the person already takes. Only after those questions clear does the labeled opening step apply, and that step is identical for everyone.
Dr. Henry Sobo, MD, Internal Medicine
Indication comes before anything else
Ozempic is approved for adults with type 2 diabetes as an addition to diet and exercise, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. That second indication is grounded in a cardiovascular outcomes trial rather than inferred, and it changes how the drug is positioned for a patient who has both conditions.
It is not the semaglutide product approved for chronic weight management. Wegovy holds that indication, with its own labeling and its own titration path. A clinician who determines that weight management is the actual goal is choosing between different products, not adjusting the same one, and current obesity pharmacotherapy guidance treats those as distinct decisions.
Getting this wrong at the start produces mismatched expectations that surface weeks later, usually as a complaint that the drug is underperforming against a benchmark it was never measured on.
Because that distinction gets blurred online, it helps to see how a provider frames the drug before booking. Henry Meds and Ro describe it as a type 2 diabetes treatment on their information pages, and HealthRX does the same on its page for Ozempic, while a manufacturer route like LillyDirect points patients to the official material. None of that replaces the intake described below, but the way a service states the indication is an early signal of whether it treats screening as a real step or a formality.
The histories that stop the conversation
Semaglutide carries a boxed warning based on thyroid C-cell tumors seen in rodent studies. Whether that finding translates to humans is unresolved, but the labeling response is unambiguous: the drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, and in anyone with multiple endocrine neoplasia syndrome type 2.
A family history question is therefore not paperwork. It is the single screening item that can end the assessment, and it depends on information only the patient holds. Prior serious hypersensitivity to semaglutide is also a contraindication.
Other histories change the shape of the plan without necessarily stopping it. Prior pancreatitis, existing gallbladder disease, gastroparesis or another motility disorder, active diabetic retinopathy, and a history of severe gastrointestinal intolerance to an earlier GLP-1 all belong in the record before a first prescription is written.
What a proper intake covers
| What is asked | What it changes |
|---|---|
| Personal or family thyroid cancer history | Can rule the drug out entirely |
| Current insulin or sulfonylurea use | Other agents may need adjusting to avoid low blood sugar |
| Pregnancy, breastfeeding, or plans to conceive | Changes whether treatment proceeds and when |
| Baseline A1C and glucose pattern | Sets what the treatment is being measured against |
| Kidney function and hydration history | Vomiting-related decline is the main renal concern |
| Prior GLP-1 experience | Predicts tolerance and may justify a slower ramp |
| Upcoming surgery or endoscopy | Delayed gastric emptying affects procedure planning |
An intake that skips the medication list is the one most likely to cause harm early. Semaglutide alone rarely causes low blood sugar, but combined with insulin or a sulfonylurea the risk is real, and diabetes standards of care treat reviewing those combinations as part of starting any new glucose-lowering agent.
Why the opening step is the same for everyone
Patients often expect a starting amount scaled to their size, the way some medications are. Semaglutide is not dosed that way. The labeled opening step is fixed, and the prescribing information states that it is for treatment initiation rather than for glycemic control.
The reason is that the first weeks are testing tolerance, not treating anything. Gastrointestinal adaptation does not track body weight in a predictable way, so there is nothing to scale against. A larger person and a smaller one are equally likely to have a difficult first month.
This is also why an early absence of results is not evidence of a wrong prescription. The labeling anticipates it.
How the plan should be documented before the first injection
A useful starting plan states four things: what the treatment is aiming at, what will be measured and when, under what circumstances a step would be held or reduced, and who to contact between visits. Written down, those four answers make the difference between a managed course and a series of improvised decisions.
Access route affects how completely that plan gets made. A primary care or endocrinology practice that already holds the chart starts with the history. Manufacturer channels such as NovoCare Pharmacy and LillyDirect connect a patient to a prescriber and dispense the branded product. Direct-to-consumer telehealth companies including Ro, Hims & Hers, LifeMD, WeightWatchers Clinic, and FormBlends run their own intake, and the depth of that intake varies. Whichever route a patient uses, it is reasonable to ask the provider behind it what the clinician actually reviews and whether the same clinician stays with the case.
A thin intake looks recognizable once described. It asks height, weight, and a short checklist, produces an immediate approval, and never asks a follow-up question about anything the patient reported. Screening questions that cannot rule anyone out are decoration.
Compounded preparations do not import the label
Compounded semaglutide is not FDA-approved. There is no reviewed label establishing a concentration, a device, or a titration path, and concentrations differ between compounding pharmacies. The numbers in approved labeling describe the approved product and nothing else, so a starting approach for a compounded preparation comes from the prescriber and pharmacy involved rather than from anything published for the branded pen.
The clinical screening described above still applies in full. Contraindications belong to the molecule and the patient, not to the supply route.
Frequently asked questions
Does a higher body weight mean a higher starting amount?
No. The labeled opening step is fixed rather than weight-based, because the first weeks assess gastrointestinal tolerance rather than treat blood sugar. Tolerance does not scale with body size in a way that would justify a different starting point.
What single history item most often rules the drug out?
A personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2. Both are listed contraindications tied to the boxed warning, and both depend
By
